Urologix, Inc. (ULGX)

Market Cap	4.26K -97.1%
Revenue (ttm)	12.00M -19.4%
Net Income	-4.67M
EPS	-0.22
Shares Out	21.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280
Average Volume	16,266
Open	0.0002
Previous Close	0.0001
Day's Range	0.0002 - 0.0002
52-Week Range	0.0000 - 0.0251
Beta	-126.31
RSI	48.37
Earnings Date	n/a

About Urologix

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1991
• Employees: 61
• Stock Exchange: OTCMKTS
• Ticker Symbol: ULGX

Financial Performance

In fiscal year 2014, Urologix's revenue was $14.01 million, a decrease of -15.00% compared to the previous year's $16.48 million. Losses were -$7.61 million, 77.3% more than in 2013.